

Takanori Ito

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3637812/takanori-ito-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18
papers

158
citations

7
h-index

12
g-index

21
ext. papers

245
ext. citations

4.2
avg, IF

2.59
L-index

#	Paper	IF	Citations
18	Changes in Body Composition Predict the Time to Treatment Failure of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma: A Pilot Retrospective Study.. <i>Nutrition and Cancer</i> , 2022 , 1-10	2.8	
17	Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancer Investigation</i> , 2021 , 1-10	2.1	1
16	Impact of visceral fat accumulation on the prognosis of patients with cirrhosis. <i>Clinical Nutrition ESPEN</i> , 2021 , 42, 354-360	1.3	0
15	Filtrated Adipose Tissue-Derived Mesenchymal Stem Cell Lysate Ameliorates Experimental Acute Colitis in Mice. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 1034-1044	4	3
14	Progression After Molecular Targeted Agents: Hepatic Arterial Changes and Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>In Vivo</i> , 2021 , 35, 1185-1189	2.3	0
13	Factors associated with bleeding after endoscopic variceal ligation in children. <i>Pediatrics International</i> , 2021 , 63, 1223-1229	1.2	0
12	Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. <i>Hepatology International</i> , 2021 , 15, 1278-1287	8.8	4
11	Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study. <i>Medicine (United States)</i> , 2021 , 100, e26820	1.8	0
10	Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis. <i>Scientific Reports</i> , 2021 , 11, 18778	4.9	1
9	Cationic surface charge effect on proliferation and protein production of human dental pulp stem cells cultured on diethylaminoethyl-modified cellulose porous beads. <i>Biochemical Engineering Journal</i> , 2021 , 176, 108217	4.2	1
8	Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. <i>Journal of Gastroenterology</i> , 2020 , 55, 653-661	6.9	14
7	Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report. <i>Clinical Journal of Gastroenterology</i> , 2020 , 13, 397-402	1.1	3
6	Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2020 , 50, 374-381	5.1	17
5	Spleen stiffness by 2-D shear wave elastography is the most accurate predictor of high-risk esophagogastric varices in children with biliary atresia. <i>Hepatology Research</i> , 2019 , 49, 1162-1168	5.1	13
4	Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. <i>Hepatology Research</i> , 2019 , 49, 1054-1065	5.1	28
3	Influence of proton pump inhibitors on microbiota in chronic liver disease patients. <i>Hepatology International</i> , 2019 , 13, 234-244	8.8	14
2	Secreted Ectodomain of SIGLEC-9 and MCP-1 Synergistically Improve Acute Liver Failure in Rats by Altering Macrophage Polarity. <i>Scientific Reports</i> , 2017 , 7, 44043	4.9	23

- 1 Multifaceted Therapeutic Benefits of Factors Derived From Dental Pulp Stem Cells for Mouse Liver Fibrosis. *Stem Cells Translational Medicine*, **2016**, 5, 1416-1424 6.9 36